By the end of this video, you will be able to contrast
the ADME properties of biologics against those
of small molecules. You will also be able to
connect the ADME properties of biologics to how they are
administered and dosed. On the screen are names of four different highly
successful drugs, two, ibrutinib and lenalidomide are considered small molecule drugs. Note the molecular weights of these drugs are
relatively small. Small molecules typically have a molecular weight
under 1,000 g/mol, often less than 500 g/mol. The other two drugs are biologic drugs, dulaglutide
and pembrolizumab. These drugs consists of
proteins and therefore their molecular weights are listed in the
manner of proteins. Dulaglutide is a
fusion protein with a molecular weight
of 63 kilodaltons, the same as 63,000 g/mol. Pembrolizumab is
actually an antibody huge with a massive
149 kilodaltons. In addition, these biologics are made of naturally
occurring amino acids, while the small molecule
drugs are organic, non naturally occurring
xenobiotic compounds. The difference is in
molecular weight, as well as their
chemical makeup have a large effect on the ADME
properties of these drugs. Let's look at these
ADME differences. For absorption, small molecules tend to have higher
membrane permeability, which favors oral absorption. Biologics have poor membrane permeability
and oral bioavailability. Because biologics do
not cross membranes, they are confined
to the plasma and interstitial fluids and have
low volume of distribution. Unlike small molecules, biologics are too large
to enter liver cells, so they're hepatic clearance
is essentially negligible. Likewise, renal
clearance is also not a major elimination
pathway because proteins are too large to
be filtered by the kidneys. What is typically observed, especially in the case of
monoclonal antibodies, is clearance via intracellular lysosome will
proteolytic degradation. Finally, biologics that are monoclonal antibodies
are fusions of a therapeutic antibody also undergo a process
called Fc recycling that extra greatly extend serum half-life of
these molecules. Let's see how these
differences in volume of distribution and clearance
effect these drugs. In the upper right corner
is the formula for calculating half-life
from volume of distribution and clearance. Ibrutinib and lenalidomide or
both once a day oral drugs. The volume of distribution
and clearance for oral drugs vary but they often work out to give a half-life
in the range of 4-16 hours. Now look at the biologics. Both have a tiny clearance to give a very long half-life, 22 days for pembrolizumab and
five days for dulaglutide. Pembrolizumab is not
orally available and must be administered
by IV infusion. This administration is
inconvenient for the patient, but the long half-life allows a three or six-week
window between doses. Dulaglutide also is not
orally available and it must be administered through
subcutaneous injection. With a long half-life, patients can go a week
or more between doses. The high molecular weight of biologics has a large effect, arguably an advantageous effect
on some ADME properties. However, the high molecular
weight of biologics also carries potential
PK and safety risks. Small molecules normally do not interact with
the immune system. The biologics are often
large foreign proteins that can trigger an
immune response. For most biologics,
with the exception of vaccines and immune response is undesirable and can lead
to rapid degradation or inactivation of the therapeutic negating any benefit
to the patient. In rare cases, an anaphylactic
reaction is also possible, representing an
important safety risk. Both these risks can be mitigated by constructing
the biologic in such a way that is
either identical to or closely resembles
a human protein. Given these immunogenicity
risks are species dependent. Biologics are often assessed
in non-human primate models. Although the immune response
in non-human primate does not predict a
similar risk in humans, the consequences of
an immune response can inform the human situation. Since immunogenicity can be
a challenge for biologics, it must be closely
monitored during pre-clinical and clinical phases of drug discovery
and development. We have now described how ADME properties differ
between small molecules and biologics and how these differences affect
the administration, dosing, efficacy, and
safety of biologics.